MARCO and cholangiocarcinoma: The present study found that a majority of solid tumors have decreased MARCO expression compared with controls, including bladder cancer, colon cancer, cholangiocarcinoma, lung cancer, HCC, ovarian cancer, prostate cancer, breast cancer, adrenocortical carcinoma, esophageal cancer, gastric cancer, endometrial cancer, and uterine sarcoma.